FDA recently approved Johnson & Johnson’s long-acting atypical antipsychotic, Invega Hafyera, the first and only twice yearly injectable to treat schizophrenia in adults.
Providers...
Novartis and NHS England recently reached a commercial agreement to enable broad access to Novartis’ RNA therapy, Leqvio, which helps lower LDL cholesterol (LDL-C) in eligible patients with...
Eli Lilly and Company recently entered into a multi-year research collaboration and licensing agreement with Lycia Therapeutics to discover, deliver, and commercialize novel targeted drug...
The AMA, American Pharmacists Association (APhA), and American Society of Health-System Pharmacists (ASHP) have called for an “immediate end” to the prescribing, dispensing, and use of...
Pfizer and BioNTech recently signed a letter of intent with Eurofarma Laboratoriors SA, a Brazilian pharmaceutical company, to manufacture its COVID-19 vaccine, Comirnaty, in Latin...
Johnson & Johnson recently announced that a booster dose of its COVID-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after...
Digital therapeutics present potential solutions for chronic diseases management, ranging from Alzheimer’s disease, type 2 diabetes, congestive heart failure, and cancer. The same technologies...
GoodRx and Boehringer Ingelheim recently collaborated to increase affordable drug access for patients with type 2 diabetes or chronic obstructive pulmonary disease (COPD).
Under the...
The University of Pittsburgh Medical Center (UPMC) recently announced expanded access to its potential COVID-19 antibody treatments in outpatient and inpatient settings for eligible...
The World Health Organization (WHO) recently announced the next phase in its Solidarity trial, Solidarity PLUS, to test new COVID-19 drugs in hospitalized patients.
The trial will enroll...
Merck recently announced that FDA accepted for review a new supplemental Biologics License Application seeking approval for its antibody, Keytruda, for patients with advanced endometrial...
Bayer recently entered into a pharma acquisition deal with Vividion Therapeutics to unlock high value, traditionally undruggable targets with precision therapeutics.
Vividion will leverage its...
Kite and Appia Bio recently collaborated to research and develop HSC-derived allogeneic cell therapies for cancers.
Under the collaboration, the companies will develop chimeric antigen receptor...
Over half of retail pharmacy customers (51 percent) have used health and wellness services over the past year, according to the J.D. Powers 2021 US Pharmacy Study.
This number is up from...
FDA recently approved GSK’s Nucala, a monoclonal antibody that targets interleukin-5, as a treatment for patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
The new indication for...
Sanofi and Translate Bio recently entered into a $3.2 billion pharma acquisition deal to accelerate the development of mRNA vaccines and therapeutics.
Under the terms of the acquisition,...
FDA recently accepted Roche’s biologics license application and granted priority review for Tecentriq as an adjuvant treatment following surgery and platinum-based chemotherapy for individuals...
Eli Lilly and Company and Kumquat Biosciences recently entered into a multi-year collaboration to discover, develop, and commercialize potential small molecule drug candidates that stimulate...
AstraZeneca recently announced that its COVID-19 vaccine, Vaxzevria, was 82 percent effective against hospitalization or death caused by the Beta/Gamma SARS-CoV-2 variants.
The results,...
FDA recently approved Merck’s anti-PD-1 therapy, Keytruda, for the treatment of patients with high-risk, early-stage triple-negative breast cancer (TNBC) in combination with...
